CTI 156
Alternative Names: CTI-156Latest Information Update: 28 Jan 2021
At a glance
- Originator Cellics Therapeutics
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 13 Jan 2021 CTI 156 is available for licensing as of 13 Jan 2021. https://cellics.com/business-development/
- 13 Jan 2021 Preclinical trials in Osteoarthritis in USA (unspecified route) before January 2021 (Cellics Therapeutics pipeline, January 2021)
- 13 Jan 2021 Preclinical trials in Rheumatoid arthritis in USA (unspecified route) before January 2021 (Cellics Therapeutics pipeline, January 2021)